These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34061690)

  • 1. Determination of Asenapine Maleate in Pharmaceutical and Biological Matrices: A Critical Review of Analytical Techniques over the Past Decade.
    Kotak V; Tanna N; Patel M; Patel R
    Crit Rev Anal Chem; 2022; 52(8):1755-1771. PubMed ID: 34061690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Optimization of Asenapine Sublingual Film Using QbD Approach.
    Dalal R; Shah J; Gorain B; Choudhury H; Jacob S; Mehta TA; Shah H; Nair AB
    AAPS PharmSciTech; 2021 Oct; 22(7):244. PubMed ID: 34608546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders.
    Reyad AA; Mishriky R
    Psychiatr Danub; 2019 Jun; 31(2):157-161. PubMed ID: 31291219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.
    Tarazi FI; Shahid M
    Drugs Today (Barc); 2009 Dec; 45(12):865-76. PubMed ID: 20135021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asenapine: a review of acute and extension phase data in bipolar disorder.
    McIntyre RS
    CNS Neurosci Ther; 2011 Dec; 17(6):645-8. PubMed ID: 20950326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.
    McIntyre RS; Wong R
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):217-20. PubMed ID: 22182459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asenapine: a clinical review of a second-generation antipsychotic.
    Stoner SC; Pace HA
    Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asenapine: a new antipsychotic option.
    Henry JM; Fuller MA
    J Pharm Pract; 2011 Oct; 24(5):447-51. PubMed ID: 22156709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia.
    El-Tokhy FS; Abdel-Mottaleb MMA; El-Ghany EA; Geneidi AS
    Int J Pharm; 2021 Oct; 608():121080. PubMed ID: 34506923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
    Chwieduk CM; Scott LJ
    CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):893-903. PubMed ID: 24793403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asenapine review, part II: clinical efficacy, safety and tolerability.
    Citrome L
    Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics and biodistribution studies of asenapine maleate using novel and sensitive RP-HPLC method.
    Managuli RS; Gourishetti K; Shenoy RR; Koteshwara KB; Reddy MS; Mutalik S
    Bioanalysis; 2017 Jul; 9(14):1037-1047. PubMed ID: 28737445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of asenapine formulations.
    Suresh A; Narayan R; Nayak UY
    Expert Opin Drug Deliv; 2020 Oct; 17(10):1377-1393. PubMed ID: 32633149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asenapine versus placebo for schizophrenia.
    Hay A; Byers A; Sereno M; Basra MK; Dutta S
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011458. PubMed ID: 26599405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of asenapine treatment in clinical practice: Recommendations from a panel of experts.
    Vieta E; Montes JM; Iborra P; Mozos A; Sáez C; Benabarre A
    Rev Psiquiatr Salud Ment (Engl Ed); 2019; 12(3):163-169. PubMed ID: 29960863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of nanoemulsion components for asenapine maleate using validated RP-HPLC method.
    Kumbhar SA; Kokare CR; Shrivastava B; Gorain B
    Ann Pharm Fr; 2020 Sep; 78(5):379-387. PubMed ID: 32387177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
    Stepanova E; Grant B; Findling RL
    Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.